OncoDecipher
Identifying Silent Mutations for Cancer Classification and Prognosis
Company Overview
Snapshot
Founded in September 2021 by Tamir Tuller, OncoDecipher operates with 1–10 employees. The company secured seed funding in September 2021, with Sanara Ventures participating as a lead investor. In April 2026, OncoDecipher ceased operations.
Business overview
OncoDecipher is a Health Tech & Life Sciences company developing a computational biology platform. This platform is designed to identify silent mutations, aiming to improve pharmaceutical companies' ability to identify patients who will benefit from specific treatments. The company operates in the Pharma & Medical Biotechnology sector, focusing on Test Diagnostics & Screening, and leverages Artificial Intelligence and Machine Learning technologies.
Strategic signal
In April 2026, OncoDecipher ceased operations. This indicates a significant and recent change in the company's trajectory, signaling to investors and innovation teams that the venture is no longer active in the market.
Log in to access full profile ›Company Intelligence Q&A
- When was OncoDecipher founded?
- OncoDecipher was founded in September 2021 by Tamir Tuller.
- What is OncoDecipher's primary focus?
- OncoDecipher focuses on developing a computational biology platform to identify silent mutations, aiming to improve patient identification for pharmaceutical treatments.
- What was the last known funding event for OncoDecipher?
- In September 2021, OncoDecipher secured seed funding, with Sanara Ventures participating as a lead investor.
- What is the current operational status of OncoDecipher?
- OncoDecipher ceased operations in April 2026.
- What technology does OncoDecipher utilize?
- OncoDecipher utilizes artificial intelligence and machine learning within its computational biology platform.